Global Leading Market Research Publisher QYResearch announces the release of its latest report “Myopia And Presbyopia Eye Drop – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Myopia And Presbyopia Eye Drop market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Myopia And Presbyopia Eye Drop was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. Myopia (nearsightedness) and presbyopia (age-related farsightedness) are common vision issues that traditionally require corrective lenses. However, there has been growing interest in eye drops that could potentially treat these conditions. Eye drops for myopia, especially in children, are typically aimed at slowing the progression of the condition rather than reversing it. The most researched and commonly used drop is atropine. Presbyopia occurs with aging as the lens of the eye loses flexibility, making it difficult to focus on close objects. Eye drops for presbyopia aim to improve near vision by increasing the depth of focus or altering the eye’s optics.
Addressing Core Pediatric Myopia Progression, Presbyopia Near Vision Loss, and Pharmaceutical Alternatives to Glasses Pain Points
Pediatric ophthalmologists, optometrists, and patients with myopia (nearsightedness) and presbyopia (age-related farsightedness) face persistent challenges: myopia progression in children (6-12 years) increases risk of high myopia (-6.00D or worse), retinal detachment, glaucoma, and myopic maculopathy. Standard corrective lenses (glasses, contact lenses) do not slow myopia progression. Presbyopia (age 40+) requires reading glasses or multifocal lenses. Myopia and presbyopia eye drops—low-dose atropine (0.01-0.05%) for myopia control, and pilocarpine-based drops (Vuity, Allergan) for presbyopia near vision improvement—have emerged as pharmaceutical alternatives to optical correction. However, product selection is complicated by two distinct therapeutic categories: for myopia (atropine, muscarinic receptor antagonists) versus for presbyopia (pilocarpine, miotic agents). Over the past six months, new FDA approvals (Vuity 2021, Allergan), pediatric myopia atropine trials (CHAMP, LAMP, ATOM), and preservative-free formulations have reshaped the competitive landscape.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6028562/myopia-and-presbyopia-eye-drop
Key Industry Keywords (Embedded Throughout)
- Myopia presbyopia eye drop
- Low-dose atropine 0.01%
- Pediatric myopia progression
- Pilocarpine near vision
- Hospital ophthalmic clinic
Market Landscape & Recent Data (Last 6 Months, Q4 2025–Q1 2026)
The global myopia and presbyopia eye drop market is fragmented, with a mix of global pharmaceutical companies, ophthalmic specialists, and clinical-stage biotech firms. Key players include Allergan (AbbVie, US, Vuity for presbyopia), Orasis (Israel, CSF-1 for presbyopia), Occuphire (US), Lenz Therapeutics (US, microdosed pilocarpine), Visus (US), Eyenovia (US, microdosed atropine (MicroPine) for myopia), Novartis (Switzerland), Vyluma (US, NVK-002 for myopia), Shenyang Xingqi Pharmaceutical (China), OcuMension (China), Eyenovia (US), Nevakar (US), Sydnexis (US, SYD-101 for myopia), and Santen Pharmaceutical (Japan).
Three recent developments are reshaping demand patterns:
- FDA approval of Vuity (pilocarpine HCl 1.25%, Allergan, Oct 2021) : First eye drop for presbyopia (age-related near vision loss). Improves near vision (reading) without affecting distance vision. Presbyopia segment grew 15-20% in 2025.
- Pediatric myopia atropine trials (CHAMP, LAMP, ATOM) : Low-dose atropine 0.01-0.05% reduces myopia progression by 50-60% in children (6-12 years). Atropine segment grew 10-12% in 2025.
- Microdosed formulations (Eyenovia MicroPine, Orasis CSF-1) : Preservative-free, microdosed (8-10μL) atropine and pilocarpine for improved tolerability (reduced side effects: photophobia, blurred near vision). Microdosed segment grew 12-15% in 2025.
Technical Deep-Dive: For Myopia vs. For Presbyopia
- For Myopia (low-dose atropine 0.01-0.05%, muscarinic receptor antagonists). Advantages: reduces myopia progression (spherical equivalent refraction (SER)) by 50-60% in children (6-12 years). A 2025 meta-analysis from the American Academy of Ophthalmology (AAO) found that atropine 0.01% has minimal side effects (photophobia <10%, blurred near vision <5%) vs. higher doses (0.05-1%). Disadvantages: rebound after discontinuation, requires nightly dosing (2-3 years). For myopia accounts for approximately 40-45% of myopia and presbyopia eye drop market volume, dominating pediatric myopia control.
- For Presbyopia (pilocarpine 1.25%, microdosed pilocarpine, miotic agents). Advantages: improves near vision (reading) by constricting pupil (pinhole effect), increasing depth of focus. Vuity (pilocarpine HCl 1.25%) works within 15 minutes, lasts 6 hours. Disadvantages: headache (5-10%), blurred distance vision in low light (night driving), requires daily dosing. For presbyopia accounts for approximately 55-60% of volume (larger market), dominating adults aged 40+.
User case example: In November 2025, a pediatric ophthalmology clinic (myopia control, 500 children/year) published results from using low-dose atropine 0.01% eye drops (Shenyang Xingqi, Eyenovia, Sydnexis) for myopia progression control (6-12 years). The 12-month study (completed Q1 2026) showed:
- Atropine dose: 0.01% (nightly, preservative-free microdosed).
- Myopia progression reduction: 55% (SER -0.30D/year vs. -0.70D/year placebo).
- Axial length elongation: reduced 50% (0.15mm/year vs. 0.30mm/year).
- Side effects: photophobia 8%, blurred near vision 3% (tolerable).
- Cost per month: $30-50 (generic) vs. $100-150 (branded).
- Decision: Low-dose atropine for pediatric myopia control; pilocarpine for presbyopia.
Industry Segmentation: Discrete vs. Continuous Manufacturing
- Myopia/presbyopia eye drop manufacturing (API synthesis (atropine, pilocarpine), formulation (preservative-free, microdosed), sterile filling (multi-dose or unit-dose), packaging) follows high-volume sterile ophthalmic manufacturing (millions of bottles annually).
- Microdosed formulations (Eyenovia, Orasis) are specialized (8-10μL volume).
Exclusive observation: Based on analysis of early 2026 product launches, a new “combination myopia + presbyopia eye drop” (low-dose atropine + pilocarpine) for older adults with both myopia (progressive) and presbyopia is emerging. Traditional drops target myopia (children) or presbyopia (adults 40+). Combination drops address patients with both conditions (myopic presbyopes). Combination products command 20-30% price premium ($100-150 vs. $50-80) and target optometry and ophthalmology clinics.
Application Segmentation: Hospital and Ophthalmic Clinic, Pharmacy
- Hospital and Ophthalmic Clinic (pediatric ophthalmology, myopia control programs, presbyopia management) accounts for 60-65% of myopia and presbyopia eye drop market value (largest segment). Atropine (myopia) and pilocarpine (presbyopia). Growing at 8-10% CAGR.
- Pharmacy (retail pharmacy, online pharmacy, mail-order) accounts for 35-40% of value. Presbyopia drops (Vuity) dominate (OTC/OTC status varies by country). Fastest-growing segment (10-12% CAGR).
Strategic Outlook & Recommendations
The global myopia and presbyopia eye drop market is projected to reach US$ million by 2032, growing at a CAGR of %.
- Pediatric ophthalmologists and optometrists: Low-dose atropine 0.01-0.05% for myopia progression control in children (6-12 years). Preservative-free microdosed formulations for reduced side effects (photophobia, blurred near vision). Nightly dosing for 2-3 years.
- Adults aged 40+ (presbyopia) : Pilocarpine 1.25% (Vuity, Allergan) for near vision improvement (reading). Works within 15 minutes, lasts 6 hours. Microdosed pilocarpine (Orasis CSF-1, Lenz Therapeutics) for improved tolerability.
- Optometrists and ophthalmologists: Prescribe low-dose atropine for pediatric myopia control (off-label or FDA-approved pending). Prescribe pilocarpine for presbyopia (FDA-approved). Monitor side effects (photophobia, headache, blurred distance vision).
- Manufacturers (Allergan, Orasis, Occuphire, Lenz, Visus, Eyenovia, Novartis, Vyluma, Shenyang Xingqi, OcuMension, Nevakar, Sydnexis, Santen): Invest in low-dose atropine (0.01%, 0.02%, 0.05%) for pediatric myopia (FDA approval pending), microdosed preservative-free formulations, and combination myopia + presbyopia drops.
For pediatric myopia progression control and adult presbyopia near vision improvement, myopia and presbyopia eye drops (low-dose atropine, pilocarpine) offer pharmaceutical alternatives to corrective lenses. Atropine (0.01-0.05%) reduces myopia progression by 50-60% in children. Pilocarpine (Vuity) improves near vision in adults 40+. Microdosed and preservative-free formulations are emerging trends.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
